Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr

Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr


Yes Bank reported 44.75% jump in standalone net profit to Rs 1,068.42 crore on 0.27% increase in total income to Rs 9,381.07 crore in Q4 FY26 over Q4 FY25.

Operating profit (before provisions and contingencies) stood at Rs 1,618.24 crore in Q4 March 2026 , registering the growth of 23.12% compared with Rs 1,314.38 crore in Q4 March 2025.

Net interest income (NII) increased 15.9% YoY to Rs 2,638 crore in Q4 FY26. Net interest margin (NIM) jumped 20 bps to 2.7% aided by lower cost of deposits and reduction in balances of PSL shortfall deposits

On the balance sheet front, total deposits grew 12.1% YoY to Rs 3,18,969 crore in Q4 FY26. CASA Deposits stood at Rs 1,11,959 crore, up 14.9% YoY. Net advances stood at Rs 2,73,445 crore, up 11.1% YoY, driven by acceleration across business segments.

 

The banks gross non-performing assets (NPA) ratio declined to 1.3%, down 30 bps YoY, while the net NPA ratio fell to 0.2%, down 10 bps YoY. The provision coverage ratio rose to 81.9%, compared with 79.7% in Q4 FY25. Gross slippages increased to Rs 1,102 crore, or 1.6% of advances in Q4 FY26, with retail slippages at 2.8% of advances were at their lowest level in nine quarters. Recoveries and upgrades stood at Rs 1,547 crore, including a Rs 446 crore gain from security receipts.

On an annual basis, the companys standalone net profit climbed 44.46% to Rs 3,475.59 crore on 0.46% rise in total income to Rs 36,928.17 crore in FY26 over FY25.

Vinay M. Tonse, managing director & CEO, YES Bank said, YES BANK concluded FY26 on a strong footing, delivering a Q4 RoA of 1.0% in line with our guidance, supported by a 20 bps improvement in NIMs, improvement in Cost to Income ratio and the lowest GNPA and NNPA levels since FY20. Business momentum continued to strengthen, with broad-based growth across advances and deposits, underpinned by a robust CASA-led deposit engine that contributed to lower Cost of Deposits.

FY26 also marked an important strategic milestone with SMBC becoming our largest shareholder, reaffirming global institutional confidence in the Banks long-term potential. As we move into FY27, our priorities remain firmly anchored in strengthening the franchise, accelerating high-quality growth, and advancing our journey toward building a resilient YES Bank that consistently creates sustainable value for all stakeholders.

Yes Bank, a full-service commercial bank headquartered in Mumbai, offers a wide array of products, services, and digital solutions, catering to Retail, MSME, and Corporate clients. The bank operates its brokerage business through Yes Securities, a subsidiary of the bank. The bank has a pan-India presence including an International Banking Unit (IBU) at GIFT City, and a representative office in Abu Dhabi.

The counter rose 1.25% to end at Rs 20.20 on the BSE.



Source link

Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr

Cipla's manufacturing facility in Goa gets two observations in Form 483 from US FDA


Cipla said that the United States Food and Drug Administration (US FDA) has conducted an inspection at the company’s manufacturing facility in Verna, Goa, India from 6th to 17th April 2026.

The inspection was a routine current good manufacturing practices (cGMP) inspection and a pre-approval inspection (PAI).

On conclusion of the inspection, the Company received two inspectional observations in Form 483.

“The company will work closely with the US FDA and is committed to address these comprehensively within stipulated time, Cipla said in a statement.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.

 

The company reported 56.96% decrease in consolidated net profit to Rs 675.80 crore in Q3 FY26 as against Rs 1,570.51 crore in Q3 FY25. Total revenue from operations marginally rose 0.02% YoY to Rs 7,074.48 crore in Q3 FY26.

The scrip had added 0.61% to end at Rs 1238.30 on the BSE on Friday.



Source link

Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr

UltraTech Cement raises total cement production capacity in India to 200.1 MTPA


UltraTech Cement said that the company has commissioned three new cement grinding units with a cumulative capacity of 8.7 million tonnes per annum (MTPA).

The three new cement grinding units, which are located in Shahjahanpur (Uttar Pradesh), Patratu (Jharkhand), and Vizag (Andhra Pradesh), have been strategically positioned to strengthen regional supply, serving North Indias booming construction corridor, the industrial heartland of Jharkhand, and the rapidly urbanising coastal belt of Andhra Pradesh.

With the commissioning of these units, the companys installed cement manufacturing capacity in India has risen to 200.1 MTPA.

Alongwith its overseas capacity of 5.4 mtpa, the UltraTechs global capacity stands at 205.5 MTPA.

 

The company now ranks as the worlds largest cement company by sales volume and is also the largest single-country cement manufacturer globally (excluding China).

UltraTechs next phase of expansion is already underway. The projects currently underway, backed by a capex of over Rs 16,000 crore, will take the companys consolidated cement manufacturing capacity to 240-plus MTPA.

UltraTech Cement is the cement flagship company of the Aditya Birla Group. It is the second-largest cement producer in the world, outside of China. During the December quarter, the companys domestic grey cement capacity stood at 188.66 MTPA. Including its 5.4 MTPA cement capacity in the UAE, UltraTechs total global cement capacity has reached 194.06 MTPA.

The company reported a 26.92% jump in consolidated net profit to Rs 1,725.40 crore on 22.78% increase in revenue from operations to Rs 21,829.68 crore in Q3 FY26 over Q3 FY25.

The scrip rose 0.50% to end at Rs 11887.30 on the BSE on Friday.



Source link

Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr

Lupin's New Jersey-based facility gets Form-483 with three observations from US FDA


Lupin said that the United States Food and Drug Administration (U.S. FDA) has concluded an inspection at our manufacturing facility located in Somerset, New Jersey, U.S.A.

The inspection was conducted from 13 April 2026 to 17 April 2026 and closed with the issuance of a Form-483 with three observations.

“We will address the observations and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP standards across all our facilities, Lupin stated.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

 

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The scrip had shed 0.10% to end at Rs 2324.25 on the BSE on Friday.

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 18 2026 | 12:50 PM IST



Source link

Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr

Tega Industries incorporates WoS – Tega Solutions


Tega Industries has incorporated a wholly owned subsidiary Company in India in the name and style of Tega Solutions on 01 April 2026. The Company has received Certificate of Incorporation from the Ministry of Corporate Affairs on 17 April 2026.

The object of incorporation is to carry on the business of providing all kinds of management consultancy services and to act as a Global Capability Centre including Global Cost Centre for entities.

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 18 2026 | 11:50 AM IST



Source link

Yes Bank Q4 PAT climbs 45% YoY to Rs 1,068 cr

Clarion Wind Farm signs contract of Rs 8.61 cr for re-powering existing wind farm


Orient Green Power Company announced that its material step-down subsidiary, Clarion Wind Farm has executed a contract valued at Rs 8.61 crore for supply of 2 Nos of P57-750 KW Wind Turbine Generators aggregating to 1.5 MW with M/s. Pioneer Wincon Energy Systems (Pioneer) for re-powering existing wind farm at Devarkulam site, Tamil Nadu.
 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 18 2026 | 11:31 AM IST



Source link

YouTube
Instagram
WhatsApp